SAN FRANCISCO, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (VIV:TSX.V), a biotech company focused on science-based, natural health products for livestock, companion animals and humans, is making rapid headway with products for livestock in light of government mandates across the world.

Company mentioned: Avivagen Inc.

According to the Centers for Disease Control and Prevention (CDC), "each year in the U.S., at least 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result." Resistant strains also result in 8 million additional hospital days. "The antibiotic resistant bacteria that arises from the use of antibiotics in animal feed are the same 'superbugs' that infect and kill humans," stated Kym Anthony, Avivagen's chairman.

Research initiated at Canada's National Research Council and continued at Avivagen found that carotenoids, the compound that gives vegetables like carrots their bright color, are a "non-antibiotic means of maintaining optimal health and growth." Further research discovered that oxidized beta-carotene provides many times the health benefits of regular beta-carotene.

The Avivagen commercial OxBC formulations include OxC-beta™ Livestock premix for livestock feeds and Vivamune™ Health Chews supplements for companion animals. The company has reported that "numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics."

Already, Avivagen has already received approvals and begun sales in Asia, including the Philippines, Taiwan, Thailand and New Zealand.

Continue reading this article: This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers

About Streetwise Reports

Streetwise Reports shares investment ideas in many sectors. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.

The full disclosure is provided at the end of the published article: This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers

For more information, please contact Carmen Guzman, .